Information Provided By: 
Fly News Breaks for September 11, 2019
EBS
Sep 11, 2019 | 16:36 EDT
Guggenheim analyst Dana Flanders initiated Emergent BioSolutions with a Buy rating and a $65 price target. The analyst called the company "an adept acquirer," and noted that it looks ready to potentially further acquire in the MCM space. Additionally, Flanders believes Narcan is positioned for growth due to the opioid epidemic, although he noted that competition and litigation are potential issues.
News For EBS From the Last 2 Days
There are no results for your query EBS
